Tag - KTRA

Developments

Kintara Therapeutics reports interim data from two Phase 2 trials of VAL-083

Kintara Therapeutics (NASDAQ:KTRA) reported interim data from two Phase 2 trials evaluating VAL-083 for the treatment of glioblastoma multiforme (GBM). In the first Phase 2 study, newly diagnosed patients receiving VAL...

November 19, 2020

Feature

Kintara Therapeutics readies two late-stage cancer drug candidates

Kintara Therapeutics (NASDAQ:KTRA), fresh off a merger and $25-million private placement, is moving into a global registration trial in newly-diagnosed and recurrent glioblastoma multiforme (GBM), a deadly brain cancer...

November 17, 2020

Tag - KTRA

Kintara Therapeutics reports interim data from two Phase 2 trials of VAL-083

Kintara Therapeutics readies two late-stage cancer drug candidates

General

More